2 recruiting, 1 active not recruiting. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Recruiting 2, Active not recruiting 1 |
Follow Pelabresib: new trials by email Literature Review of Pelabresib trials Research Report on Pelabresib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) Pelabresib, Ruxolitinib, Placebo - Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF) | Phase 3 | Recruiting | Novartis Pharmaceuticals | 460 | 2026-05-27 | 2026-11-06 |
| An Extension Study for Patients Previously Enrolled in Studies With Pelabresib Pelabresib - Hematologic Malignancy, Solid Tumor | Phase 3 | Recruiting | Novartis Pharmaceuticals | 50 | 2024-08-13 | 2026-06-11 |
| Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) Pelabresib, Ruxolitinib, Placebo - Myelofibrosis, Primary Myelofibrosis | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 430 | 2021-04-09 | 2026-07-17 |
Primary Myelofibrosis (2) · Hematologic Neoplasms (1)
Belgium (3) · Italy (3) · Netherlands (3) · United States (3) · Australia (2) · Austria (2) · Canada (2) · Czechia (2) · France (2) · Germany (2) · Malaysia (2) · Poland (2) · South Korea (2) · Spain (2) · Taiwan (2)
2023 (2), 2025 (1)